Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tevogen Bio Holdings Inc (TVGN)

Tevogen Bio Holdings Inc (TVGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,595
  • Shares Outstanding, K 198,690
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,730 K
  • EBIT $ -31 M
  • EBITDA $ -30 M
  • 60-Month Beta -0.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.19
  • Most Recent Earnings $-0.03 on 11/14/25
  • Next Earnings Date 11/18/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3790 +5.70%
on 11/17/25
0.5483 -26.94%
on 11/06/25
-0.1244 (-23.70%)
since 11/05/25
3-Month
0.3790 +5.70%
on 11/17/25
0.9900 -59.54%
on 09/08/25
-0.4658 (-53.76%)
since 09/05/25
52-Week
0.3790 +5.70%
on 11/17/25
1.9200 -79.14%
on 01/27/25
-0.6494 (-61.85%)
since 12/05/24

Most Recent Stories

More News
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

This milestone expands patient eligibility through multi-HLA targeting Builds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk patients...

TVGNW : 0.0444 (-0.22%)
TVGN : 0.4006 (-5.00%)
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today issued a statement to provide clarity regarding its accumulated deficit...

TVGNW : 0.0444 (-0.22%)
TVGN : 0.4006 (-5.00%)
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), in ongoing community, industry, and academic engagements, has continued...

TVGNW : 0.0444 (-0.22%)
TVGN : 0.4006 (-5.00%)
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records. Potential future T cell therapies could reliably bind to their target nearly every...

TVGNW : 0.0444 (-0.22%)
TVGN : 0.4006 (-5.00%)
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

WARREN, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today highlights emerging scientific evidence linking persistent viral...

TVGNW : 0.0444 (-0.22%)
TVGN : 0.4006 (-5.00%)
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that Mittul Mehta, Chief Information Officer of Tevogen...

TVGNW : 0.0444 (-0.22%)
TVGN : 0.4006 (-5.00%)
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.”...

TVGNW : 0.0444 (-0.22%)
TVGN : 0.4006 (-5.00%)
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today shared the risk-adjusted net present value (rNPV) estimate of $9...

TVGNW : 0.0444 (-0.22%)
TVGN : 0.4006 (-5.00%)
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone. Covering five rare disease eligible indications, the accessible market in the US could be...

TVGNW : 0.0444 (-0.22%)
TVGN : 0.4006 (-5.00%)
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today highlighted the continuing need for SARS-CoV-2 treatments for individuals...

TVGNW : 0.0444 (-0.22%)
TVGN : 0.4006 (-5.00%)

Business Summary

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers. Tevogen Bio Holdings Inc., formerly known as SEMPER PAR ACQ, is based in Warren, New Jersey.

See More

Key Turning Points

3rd Resistance Point 0.4804
2nd Resistance Point 0.4642
1st Resistance Point 0.4324
Last Price 0.4006
1st Support Level 0.3844
2nd Support Level 0.3682
3rd Support Level 0.3364

See More

52-Week High 1.9200
Fibonacci 61.8% 1.3313
Fibonacci 50% 1.1495
Fibonacci 38.2% 0.9677
Last Price 0.4006
52-Week Low 0.3790

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar